4-pentyl semicarbazide | 79353-75-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-pentyl semicarbazide
• 英文别名: 1-Amino-3-pentylurea
• CAS: 79353-75-6
• 化学式: C₆H₁₅N₃O
• mdl: MFCD11212589
• 分子量: 145.205
• InChiKey: MYFMFYJXDUTRFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  溴化氰 、 4-pentyl semicarbazide 以 乙醇 、 水 为溶剂， 生成 N-Pentyl-[1,3,4]oxadiazole-2,5-diamine
  参考文献：
  名称：

  Kramer, Claus-Ruediger; Beck, Lothar, Zeitschrift fur Chemie, 1981, vol. 21, # 7, p. 267 - 268

  摘要：

  DOI：
• 作为产物：
  描述：

  N-2,2,2-trifluoroethoxycarbonylpentylamine 在 肼 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以12 g的产率得到4-pentyl semicarbazide
  参考文献：
  名称：

  轻松地一锅合成4-取代的氨基脲†

  摘要：

  用一锅两步法制备了25种4-一元和二取代的氨基脲的多样化文库。该方法包括由碳酸双（2,2,2-三氟乙基）酯或氯甲酸2,2,2-三氟乙基酯与伯胺或仲胺形成氨基甲酸酯，以及随后使氨基甲酸酯与肼相互作用以生成氨基脲。该方法允许以高收率和高纯度大规模获得4-取代的氨基脲。

  DOI：

  10.1039/c4ra12425a

文献信息

• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2013134562A1

  公开（公告）日：2013-09-12

  The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

  本发明涉及的化合物属于式(I)及其药学上可接受的盐，可用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式(I)化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARα拮抗剂的治疗有效量。本发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。本发明还涉及一种预防急性和慢性骨髓性白血病以及其他癌症发作和/或复发的方法，包括给予选择性PPARα拮抗剂的治疗有效量。
• [EN] SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE<br/>[FR] DÉRIVÉS DE L'ACIDE SQUARIQUE UTILISÉS COMME INHIBITEURS DU NICOTINAMIDE
  申请人：TOPOTARGET AS

  公开号：WO2009156421A1

  公开（公告）日：2009-12-30

  The present application discloses novel squaric acid derivatives of the formula A: from -C(=O)-, -S(=O)2-, -C(=S)- and -P(=O)(R5)-; B: -, -O-, -NR6- and -C(=O)-NR6-; D : -, -O-, -CR7R8- and -NR9; m=0-12; n = 0-12; m+n = 1-20; p=0-2; R1 : heteroaryl, aryl; R2 : H, C1-12-alkyl, C3-12-cycloalkyl, -[CH2CH2O]1-10-(C1-6-alkyl),C1-12-alkenyl, aryl, heterocyclyl, heteroaryl; R3 : C1-12-alkyl, C3-12-cycloalkyl, -[CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, heteroaryl; or R2 and R3 : N-containing heterocyclic/heteroaromatic ring; R4 and R4* : H, C1-12-alkyl, C1-12-alkenyl; and pharmaceutically acceptable salts and prodrugs thereof, and their use in the treatment of diseases/conditions caused by an elevated level of NAMPRT (inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and CPOD, osteoarthritis, osteoporosis and fibrotic diseases; dermatosis; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and viral infections, adult respiratory distress syndrome, ataxia telengiectasia).

  本申请公开了公式A的新颖方酸衍生物：来自-C(=O)-，-S(=O)2-，-C(=S)-和-P(=O)(R5)-；B：-，-O-，-NR6-和-C(=O)-NR6-；D：-，-O-，-CR7R8-和-NR9；m=0-12；n=0-12；m+n=1-20；p=0-2；R1：杂环烷基，芳基；R2：H，C1-12-烷基，C3-12-环烷基，-[CH2CH2O]1-10-(C1-6-烷基)，C1-12-烯基，芳基，杂环烷基，杂环芳基；R3：C1-12-烷基，C3-12-环烷基，-[CH2CH2O]1-10-(C1-6-烷基)，C1-12-烯基，芳基，杂环烷基，杂环芳基；或R2和R3：含氮杂环/杂芳环；R4和R4*：H，C1-12-烷基，C1-12-烯基；以及其药学上可接受的盐和前药，以及它们在治疗由NAMPRT水平升高引起的疾病/症状中的用途（炎症和组织修复紊乱，特别是类风湿关节炎，炎症性肠病，哮喘和CPOD，骨关节炎，骨质疏松症和纤维化疾病；皮肤病；自身免疫疾病，包括系统性红斑狼疮，多发性硬化，银屑病性关节炎，强直性脊柱炎，组织和器官排斥，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，虚弱，与感染和病毒感染相关的炎症，成人呼吸窘迫综合征，遗传性毛细血管扩张症）。
• [EN] NOVEL UREA AND THIOUREA DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'URÉE ET DE THIOURÉE
  申请人：TOPOTARGET AS

  公开号：WO2010023307A1

  公开（公告）日：2010-03-04

  The present application discloses compounds of formula (I) wherein X is =O, =S, =NH, =NOH and =NO-Me; A is -C(=O)-, -S(=O)2 -, -C(=S)- and P(=O)(R5)-; B is, -O-, -(CH2) 3-6-, and O-(CH2)2-5-; D is, -O-, -CR7R8 -and -NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

  本申请公开了以下式(I)的化合物，其中X为=O、=S、=NH、=NOH和=NO-Me；A为-C(=O)-、-S(=O)2-、-C(=S)-和P(=O)(R5)-；B为-O-、-(CH2)3-6-和O-(CH2)2-5-；D为-O-、-CR7R8-和-NR9；m为0-12，n为0-12，m+n为1-20；p为0-4；R1为opt.sub.杂环烷基；以及其药学上可接受的盐和前药。该申请还公开了该化合物用作治疗由尼克酰胺磷酸核糖转移酶(NAMPRT)水平升高引起的疾病或症状的药物，例如炎症和组织修复紊乱；皮肤病；自身免疫疾病，阿尔茨海默病，中风，动脉粥样硬化，再狭窄，糖尿病，肾小球肾炎，癌症，虚弱症，与感染相关的炎症和某些病毒感染，包括获得性免疫缺陷综合症（AIDS），成人呼吸窘迫综合征，遗传性共济失调。
• [EN] NOVEL PYRIDINYL ACRYLAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ACRYLAMIDE DE PYRIDINYLE
  申请人：TOPOTARGET AS

  公开号：WO2010066709A1

  公开（公告）日：2010-06-17

  The present application discloses pyridinyl acrylamide derivatives of the formula (I) wherein X is opt.subst. pyrid-3-yl, pyrid-4-yl; A is -C(=O)-, -S(=O)2-, -C(=S)-, -P(=O)(R5)- (R5 is C1-6-alkyl, C1-6-alkoxy, hydroxy); B is a single bond, -O-; D is a single bond, -O-, -CR7R8-, -NR9-; m is 0-12, n is 0-12, m+n is 1-20. The compounds are useful for the inhibiting of the enzyme nicotinamide phosphoribosyltransferase (NAMPRT), and to medical use of such pyridinyl acrylamide derivatives.

  本申请公开了式(I)的吡啶基丙烯酰胺衍生物，其中X是选择性取代的吡啶-3-基，吡啶-4-基；A是-C（=O）-，-S（=O）2-，-C（=S）-，-P（=O）（R5）-（R5为C1-6烷基，C1-6烷氧基，羟基）；B是单键，-O-；D是单键，-O-，-CR7R8-，-NR9-；m为0-12，n为0-12，m+n为1-20。这些化合物用于抑制酶烟酰胺磷酸核糖转移酶（NAMPRT）的活性，并用于这种吡啶基丙烯酰胺衍生物的医药用途。
• CARBAMOYL HYDRAZINE DERIVATIVES AS FORMYL PEPTIDE MODULATORS
  申请人：Allergan, Inc.

  公开号：US20150291511A1

  公开（公告）日：2015-10-15

  The present invention relates to carbamoyl hydrazine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the FPR receptor.

  本发明涉及羰基肼衍生物、其制备方法、含有它们的制药组合物以及它们作为FPR受体调节剂的药物使用。